Literature DB >> 14641264

Outcome of zone 1 retinopathy of prematurity.

Michael O'Keefe1, Bernadette Lanigan, Vernon W Long.   

Abstract

PURPOSE: To describe the outcome in a series of patients with pre-threshold and threshold zone 1 retinopathy of prematurity.
METHODS: We performed a retrospective analysis of 12 babies, 24 eyes, with zone 1 retinopathy of prematurity, treated between 1992 and 2002 with diode laser treatment.
RESULTS: Ten out of the 12 babies had an unfavourable outcome. The only patients with successful anatomical outcomes were those treated before threshold disease occurred. All babies had developmental delay or neurological disability.
CONCLUSION: Zone 1 retinopathy of prematurity has a poor anatomical and visual prognosis and many of the babies in our study had developmental delay and neurological disability. Earlier treatment may improve the visual outcome.

Entities:  

Mesh:

Year:  2003        PMID: 14641264     DOI: 10.1111/j.1395-3907.2003.00171.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  15 in total

1.  Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series.

Authors:  Ramak Roohipoor; Hamed Ghasemi; Fariba Ghassemi; Reza Karkhaneh; Mohammad Riazi-Esfahani; Mehdi Nili-Ahmadabadi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-15       Impact factor: 3.117

2.  Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.

Authors:  Huseyin Yetik; Murat Gunay; Sarkis Sirop; Ziya Salihoglu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-12-14       Impact factor: 3.117

3.  Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.

Authors:  Christopher K Hwang; G Baker Hubbard; Amy K Hutchinson; Scott R Lambert
Journal:  Ophthalmology       Date:  2015-02-14       Impact factor: 12.079

4.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

Authors:  Helen A Mintz-Hittner; Kathleen A Kennedy; Alice Z Chuang
Journal:  N Engl J Med       Date:  2011-02-17       Impact factor: 91.245

5.  Characteristic clinical features associated with aggressive posterior retinopathy of prematurity.

Authors:  Y J Ahn; K E Hong; H R Yum; J H Lee; K S Kim; Y A Youn; S H Park
Journal:  Eye (Lond)       Date:  2017-02-24       Impact factor: 3.775

6.  Low-dose ranibizumab administration in retinopathy of prematurity.

Authors:  Levent Tök; Lütfi Seyrek; Özlem Yalçın Tök
Journal:  Int Ophthalmol       Date:  2022-01-07       Impact factor: 2.031

7.  Treatment outcomes of combination of anti-vascular endothelial growth factor injection and laser photocoagulation in Type 1 ROP and APROP.

Authors:  Parveen Sen; Aditi Ashok Kumar Agarwal; Pramod Bhende; Suganeswari Ganesan
Journal:  Int Ophthalmol       Date:  2021-08-20       Impact factor: 2.031

8.  Long-term visual outcomes in extremely low-birth-weight children (an American Ophthalmological Society thesis).

Authors:  Rand Spencer
Journal:  Trans Am Ophthalmol Soc       Date:  2006

9.  Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.

Authors:  Eun Jee Chung; Ji Hyun Kim; Hyun Seok Ahn; Hyoung Jun Koh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-10       Impact factor: 3.117

10.  Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity.

Authors:  Odalis Arámbulo; Gabriel Dib; Juan Iturralde; Fahir Duran; Miguel Brito; João B Fortes Filho
Journal:  Clin Ophthalmol       Date:  2015-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.